BR9611278B1 - pasteurella haemolytica transgênica; vetor de expressão que codifica uma toxina lkt inativa; composição de vacina para induzir uma resposta imune protetora contra pasteurella haemolytica; vetor biológico transgênico. - Google Patents
pasteurella haemolytica transgênica; vetor de expressão que codifica uma toxina lkt inativa; composição de vacina para induzir uma resposta imune protetora contra pasteurella haemolytica; vetor biológico transgênico.Info
- Publication number
- BR9611278B1 BR9611278B1 BRPI9611278D BR9611278D BR9611278B1 BR 9611278 B1 BR9611278 B1 BR 9611278B1 BR PI9611278 D BRPI9611278 D BR PI9611278D BR 9611278 D BR9611278 D BR 9611278D BR 9611278 B1 BR9611278 B1 BR 9611278B1
- Authority
- BR
- Brazil
- Prior art keywords
- lkt
- lkt toxin
- toxin
- post
- precursor
- Prior art date
Links
- 101710170970 Leukotoxin Proteins 0.000 title abstract 16
- 239000003053 toxin Substances 0.000 title abstract 11
- 231100000765 toxin Toxicity 0.000 title abstract 11
- 241001293418 Mannheimia haemolytica Species 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000009261 transgenic effect Effects 0.000 title 2
- 239000013604 expression vector Substances 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 239000002243 precursor Substances 0.000 abstract 6
- 239000012190 activator Substances 0.000 abstract 5
- 244000005700 microbiome Species 0.000 abstract 5
- 230000001323 posttranslational effect Effects 0.000 abstract 4
- 208000002289 Bovine Respiratory Disease Complex Diseases 0.000 abstract 2
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 abstract 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010034107 Pasteurella infections Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000776 exotoxin Toxicity 0.000 abstract 1
- 239000002095 exotoxin Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 201000005115 pasteurellosis Diseases 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<b>imunidade contra leucotoxina de pasteurella haemolytica <d>. complexo de doença respiratória bovina (brd), febre do embarque, ou pasteurelose pneumônia, é uma doença multifatorial pelo que uma combinação de infecção viral, ambiente adverso e status imune deficiente podem combinar para predispor animais a infecção bacterianas. a exotoxina, ou leucotoxina (lkt), pode contribuir par patogênese prejudicando as defesas principais dos pulmões e respostas imunes subsequentes ou ocasionando inflamações com resultado de lise de leucócito. a presente invenção fornece um microorganismo modificado que produz uma toxina lkt, em que a referida toxina lkt é parcial ou totalmente inativada. em uma modalidade adicional da presente invenção, é fornecido um microorganismo modificado em que um opéron de toxina lkt incluindo um gene estrutural lkt e/ou um ativador pós-translação do organismo é parcial ou totalmente inativado. os presentes depositantes descobriram que um precursor de toxina de lkt tem atividade tóxica reduzida. de forma surpreendente, o precursor de toxina lkt é capaz de induzir uma respotas imune em um material que oferece proteção cruzada contra desafio heterólogo com um microorganismo que produz a toxina lkt. um microorganismo que produz natrualmente uma toxina lkt pode ser construído para produzir um precursor de toxina lkt inativo eliminando o ativador pós-translação do produto precursor. por conseguinte, em uma modalidade preferida o microorganismo é incapaz de produzir um ativador pós-translação do precursor de toxina lkt ou produz um ativador pós-translação inativado do precursor de toxina lkt. o ativador pós-translação pode ser um produto de gene c lkt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN6313A AUPN631395A0 (en) | 1995-11-02 | 1995-11-02 | Vaccine and biological vector(II) |
| PCT/AU1996/000685 WO1997016531A1 (en) | 1995-11-02 | 1996-11-01 | Immunity against pasteurella haemolytica leukotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9611278B1 true BR9611278B1 (pt) | 2016-05-24 |
Family
ID=3790638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9611278D BR9611278B1 (pt) | 1995-11-02 | 1996-11-01 | pasteurella haemolytica transgênica; vetor de expressão que codifica uma toxina lkt inativa; composição de vacina para induzir uma resposta imune protetora contra pasteurella haemolytica; vetor biológico transgênico. |
| BR9611278A BR9611278A (pt) | 1995-11-02 | 1996-11-01 | Imunidade contra leucotoxina de pasteurella haemolytica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9611278A BR9611278A (pt) | 1995-11-02 | 1996-11-01 | Imunidade contra leucotoxina de pasteurella haemolytica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6610307B1 (pt) |
| EP (1) | EP0862615B1 (pt) |
| JP (1) | JP3905127B2 (pt) |
| AU (1) | AUPN631395A0 (pt) |
| BR (2) | BR9611278B1 (pt) |
| CA (1) | CA2236700C (pt) |
| DE (1) | DE69631543T2 (pt) |
| ES (1) | ES2211982T3 (pt) |
| MX (1) | MX9803370A (pt) |
| NZ (1) | NZ320025A (pt) |
| WO (1) | WO1997016531A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840556A (en) | 1996-05-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Agriculture | Molecular genetic construction of vaccine strains of pasteurellaceae |
| JPH1075774A (ja) * | 1996-05-31 | 1998-03-24 | Akzo Nobel Nv | パスツレラ科の弱毒化ｒｔｘ産生細菌 |
| US6936262B2 (en) | 1997-09-25 | 2005-08-30 | Biotechnology Research And Development Corporation | LktA deletion mutant of P. haemolytica |
| ATE344326T1 (de) | 1997-09-25 | 2006-11-15 | Biotechnology Res & Dev | Lkta deletionsmutanten in p. haemolytica |
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| US10149889B2 (en) | 2005-11-25 | 2018-12-11 | Rutgers, The State University Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
| US8053406B2 (en) | 2005-11-25 | 2011-11-08 | University Of Medicine And Dentistry Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
| WO2007062150A2 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Leukotoxin compositions and therapeutic methods |
| US9370561B2 (en) | 2012-11-08 | 2016-06-21 | Merial, Inc. | Attenuated mannheimia haemolytica vaccines and methods of making and use |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| NL2018155B1 (en) | 2017-01-11 | 2018-07-25 | Intervet Int Bv | Oral vaccine against ruminant respiratory disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963487A (en) * | 1985-01-03 | 1990-10-16 | Massachusetts Institute Of Technology | Method for deletion of a gene from a bacteria |
| US5165924A (en) | 1986-01-22 | 1992-11-24 | University Of Guelph | Serum-free, cell-free vaccine effective against pneumonic pasteurellosis in cattle |
| US5885589A (en) * | 1988-04-12 | 1999-03-23 | Intervet International B.V. | Pasteurella vaccine |
| GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| US5641653A (en) * | 1989-10-31 | 1997-06-24 | The Texas A&M University System | DNA encoding Actinobacillus pleuropneumoniae hemolysin |
| CA2045950C (en) * | 1991-06-28 | 2004-05-11 | Elbarte M. Kamp | Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections |
| US5422110A (en) * | 1991-10-16 | 1995-06-06 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
| AUPN631495A0 (en) * | 1995-11-02 | 1995-11-23 | Commonwealth Scientific And Industrial Research Organisation | Vaccine and biological vector(I) |
| AU6969798A (en) * | 1997-04-15 | 1998-11-11 | Baylor College Of Medicine | (pasteurella haemolytica) vaccine |
-
1995
- 1995-11-02 AU AUPN6313A patent/AUPN631395A0/en not_active Abandoned
-
1996
- 1996-11-01 CA CA2236700A patent/CA2236700C/en not_active Expired - Lifetime
- 1996-11-01 BR BRPI9611278D patent/BR9611278B1/pt unknown
- 1996-11-01 ES ES96934209T patent/ES2211982T3/es not_active Expired - Lifetime
- 1996-11-01 JP JP51692597A patent/JP3905127B2/ja not_active Expired - Lifetime
- 1996-11-01 NZ NZ320025A patent/NZ320025A/en not_active IP Right Cessation
- 1996-11-01 DE DE69631543T patent/DE69631543T2/de not_active Expired - Lifetime
- 1996-11-01 WO PCT/AU1996/000685 patent/WO1997016531A1/en not_active Ceased
- 1996-11-01 EP EP96934209A patent/EP0862615B1/en not_active Expired - Lifetime
- 1996-11-01 BR BR9611278A patent/BR9611278A/pt not_active IP Right Cessation
- 1996-11-01 US US09/068,100 patent/US6610307B1/en not_active Expired - Lifetime
-
1998
- 1998-04-29 MX MX9803370A patent/MX9803370A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX9803370A (es) | 1998-11-30 |
| CA2236700A1 (en) | 1997-05-09 |
| DE69631543T2 (de) | 2004-09-16 |
| WO1997016531A1 (en) | 1997-05-09 |
| BR9611278A (pt) | 1999-01-26 |
| AUPN631395A0 (en) | 1995-11-23 |
| JP3905127B2 (ja) | 2007-04-18 |
| US6610307B1 (en) | 2003-08-26 |
| ES2211982T3 (es) | 2004-07-16 |
| EP0862615A1 (en) | 1998-09-09 |
| DE69631543D1 (de) | 2004-03-18 |
| EP0862615B1 (en) | 2004-02-11 |
| NZ320025A (en) | 1999-04-29 |
| CA2236700C (en) | 2010-06-29 |
| JP2000509243A (ja) | 2000-07-25 |
| EP0862615A4 (en) | 2000-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goodnow | Biology of Bordetella bronchiseptica | |
| BR9611278B1 (pt) | pasteurella haemolytica transgênica; vetor de expressão que codifica uma toxina lkt inativa; composição de vacina para induzir uma resposta imune protetora contra pasteurella haemolytica; vetor biológico transgênico. | |
| Aly et al. | Bacterial adherence to nasal mucosal cells | |
| Drake et al. | Flagella, motility and invasive virulence of Pseudomonas aeruginosa | |
| Johnson et al. | Loss of ciliary activity in organ cultures of rat trachea treated with lipo-oligosaccharide from Haemophilus influenzae | |
| Conlon et al. | Efficacy of recombinant leukotoxin in protection against pneumonic challenge with live Pasteurella haemolytica A1 | |
| ES2121820T3 (es) | Vacuna de conjugados de polisacaridos de neumococos. | |
| ES2061416T1 (es) | Ribocimas modificadas. | |
| Loosli | Synergism between respiratory viruses and bacteria | |
| KR890701758A (ko) | 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신 | |
| BR9610848A (pt) | Imunidade contra apx de toxinas rtx de actinobacillus pleuropneumoniae | |
| Tsuda et al. | Role of serotype-specific polysaccharide in the resistance of Streptococcus mutans to phagocytosis by human polymorphonuclear leukocytes | |
| McDonald et al. | Protection of guinea pigs from experimental Rocky Mountain spotted fever with a cloned antigen of Rickettsia rickettsii | |
| Kamiya et al. | Correlation between cytotoxin production and sporulation in Clostridium difficile | |
| ES8302086A1 (es) | Un procedimiento para preparar vacunas de pasteurella multocida y pasteunella haemolytica vivas modificadas con efectos veterinarios, particularmente para especies de animales bovinos, porcinos y ovinos. | |
| DeVuono et al. | Effect of L-form Streptococcus pyogenes and of lipoteichoic acid on human cells in tissue culture | |
| Bernstein et al. | Recurrent otitis media with non-typable Haemophilus influenzae: the role of serum bactericidal antibody | |
| Furesz | Poliomyelitis outbreaks in the Netherlands and Canada | |
| Taylor et al. | Interaction of Mycoplasma pulmonis with mouse peritoneal macrophages and polymorphonuclear leucocytes | |
| Ward et al. | Antibody response to outer-membrane antigens of Pseudomonas aeruginosa in human burn wound infection | |
| Setia et al. | Immunology in prevention of dental caries | |
| BR0007966A (pt) | Composições e métodos para o tratamento e a prevenção de infecção bacteriana patogênica com base na função essencial da metilação do dna na virulência bacteriana | |
| Ramalingaswami | Importance of vaccines in child survival | |
| Hamdy et al. | Efficacy of Linco-Spectin water medication on Mycoplasma synoviae airsacculitis in broilers | |
| Wilson | Infections of the airways |